Preprint · CC-BY
via bioRxiv
The coiled-coil domain of myosin-11 as a potential biomarker to detect patients with atherosclerotic cardiovascular disease risk
Takahashi, L., Tomiyama, H., Kobori, H., Hidaka, Y., Orihara, S., Satomi, K., Taguri, M., Chikamori, T., Yokoyama, U.
biorxiv · 2025
Abstract
BackgroundAtherosclerosis leads to severe clinical complications, and biomarkers that could predict its progression are highly desired. Phenotypic changes and dysregulation of smooth muscle cells contribute substantially to both subclinical and clinical atherosclerosis. Plasma levels of myosin-11, a smooth muscle cell-specific myosin, have been reported to increase in patients with clinical manifestations of atherosclerosis, including coronary artery disease and/or peripheral artery disease. This study aimed to investigate the association between circulating myosin-11 levels and atherosclerotic cardiovascular disease (ASCVD) risk in patients without symptomatic atherosclerosis.
Methods and resultsThis prospective study recruited 161 participants: 80 patients with either hypertension, dyslipidemia, or diabetes mellitus but without symptomatic atherosclerosis (ASCVD risk group); 50 patients with ischemic heart disease (IHD group); and 31 control participants (Controls). We developed rat monoclonal antibodies specific for the coiled-coil domain of myosin-11 and quantified circulating myosin-11 levels using an enzyme-linked immunosorbent assay with these antibodies. Myosin-11 levels were highest in the IHD group, followed by the ASCVD risk group. Both groups had significantly higher myosin-11 levels than Controls. The area under the receiver-operating characteristic curve of myosin-11 was 0.980 for IHD versus Controls and 0.874 for ASCVD risk versus Controls. Univariate analysis detected significant associations between myosin-11 levels and hypertension and age. The association between myosin-11 levels and hypertension remained significant after multivariate logistic regression analysis.
ConclusionsCirculating myosin-11 levels are elevated in patients with ASCVD risk. Myosin-11 levels may be a useful biomarker for stratification of asymptomatic individuals with higher risk of ASCVD.
Clinical PerspectiveO_ST_ABSWhat Is New?C_ST_ABSO_LIWe developed a sandwich enzyme-linked immunosorbent assay (ELISA) consisting of rat monoclonal antibodies specific for the coiled-coil domain of myosin-11 to detect trace concentrations of myosin-11 in blood circulation.
C_LIO_LIPlasma myosin-11 concentrations were elevated in both asymptomatic individuals with traditional risk factors for atherosclerotic cardiovascular disease and in patients with symptomatic coronary atherosclerosis.
C_LIO_LIThis elevation may be a potential marker independent of other circulating biomarkers, traditional risk score, and non-invasive imaging analyses.
C_LI
What Are the Clinical Implications?O_LICirculating myosin-11 may serve as a potential biomarker for identifying dysregulation of arterial smooth muscle cells during the progression of atherosclerosis.
C_LIO_LIFurther studies are warranted to evaluate whether myosin-11 levels, in combination with other reported biomarkers and risk scores, could aid in stratification of asymptomatic individuals with higher risk of ASCVD.
C_LI
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- bioRxiv
- DOI
- 10.1101/2025.01.28.635387
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
L., T., H., T., H., K., Y., H., S., O., K., S., M., T., T., C., & U., Y. (2025). The coiled-coil domain of myosin-11 as a potential biomarker to detect patients with atherosclerotic cardiovascular disease risk. <em>biorxiv</em>. https://doi.org/10.1101/2025.01.28.635387
Vancouver
L. T, H. T, H. K, Y. H, S. O, K. S, et al. The coiled-coil domain of myosin-11 as a potential biomarker to detect patients with atherosclerotic cardiovascular disease risk. biorxiv. 2025. doi:10.1101/2025.01.28.635387.
BibTeX
@unpublished{takahashi2025Thecoi,
title = {The coiled-coil domain of myosin-11 as a potential biomarker to detect patients with atherosclerotic cardiovascular disease risk},
author = {Takahashi, L. and Tomiyama, H. and Kobori, H. and Hidaka, Y. and Orihara, S. and Satomi, K. and Taguri, M. and Chikamori, T. and Yokoyama, U.},
journal = {biorxiv},
year = {2025},
doi = {10.1101/2025.01.28.635387},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Cardiovascular Medicine 2026
Open access · CC-BY
The role of IL-6 in atherosclerosis: a narrative review
The journal of nutrition health & aging 2026
Open access · CC-BY
Fatigue, muscle fatigability, and the Hallmarks of Aging: a narrative review
The journal of nutrition, health & aging 2026
Open access · OA
Fatigue, muscle fatigability, and the Hallmarks of Aging: a narrative review.
European journal of ecology, biology and agriculture. 2026
Open access · CC-BY
Impact of Systemic Inflammatory Biomarkers on Atherosclerotic Progression and Clinical Outcomes in Women: A Case-Control Study
JAMA Neurology 2019
Open access · OA
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease
The Journal of Prevention of Alzheimer s Disease 2024
Open access · CC-BY